The agreement with Anson Funds and Cable Car Capital could provide MEI Pharma with additional resources and strategic support, potentially enhancing its business operations and financial performance. The commitment to a capital return of up to $3.15 per share could make the company's stock more attractive to investors, potentially driving up its price in the short term.